Norton Rose Fulbright advises financial institutions on PLN 800 million financing for Polpharma S.A.

Global law firm Norton Rose Fulbright advised a consortium formed by domestic and international financial institutions on the PLN 800 million (€177 million) unsecured financing granted to Zakłady Farmaceutyczne Polpharma S.A. The funds will be used for the purpose of refinancing, financing of capex and working capital requirements and the financing of R&D projects and green economy transition investments. 

The syndicate of the lenders included BNP Paribas Bank Polska S.A. as facility agent and Powszechna Kasa Oszczędności Bank Polski S.A., Santander Bank Polska S.A. and European Bank of Reconstruction and Development as lenders.

The Warsaw team was led by counsel Marta Kawecka and included associate Karolina Majcher. The team worked under the supervision of partner Grzegorz Dyczkowski who heads the Warsaw office and the firm’s Warsaw banking and finance practice. Partner James Dunnett provided English law advice.

Marta Kawecka commented: ‘It was really inspiring to advise on a financing of one of the most innovative companies in the Polish pharma market and contribute to green economy transition in the pharmaceutical industry.’

Polpharma S.A. is the largest Polish manufacturer of pharmaceuticals and a leader of the Polish pharmaceutical market. The firm actively operates in the markets of Central and Eastern Europe, the Caucasus and Central Asia.